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The pathogenesis and complications of type 2 diabetes (T2DM) are closely linked with defective 
glucose metabolism, obesity, cardiovascular disease and an inability to mount an effective immune 
response to certain pathogenic organisms. Perturbations in key innate immune receptors known as 
Toll-like receptors (TLRs) and inflammatory mediators such as IL-6, TNFα and IL-1β have been linked 
with T2DM. Herein, we sought to establish whether patients with T2DM and underlying complications 
exhibit perturbations in cytokine and TLR expression. Serum cytokine and mRNA levels of cytokines/
TLRs in monocytes (M) and neutrophils (N) were measured in a cohort of 112 diabetic patients: good 
glycaemic control without complications (GC), good glycaemic control with complications (GCC), poor 
glycaemic control without complications (PC) and poor glycaemic control with complications (PCC) and 
compared them with 34 non-diabetic volunteers (NGT). Serum cytokine levels were normal in all study 
participants. In the GC group, cytokine and TLR gene expression were enhanced compared to NGT. In 
contrast, suppressed cytokine and TLR gene expression were evident in PC, GCC & PCC groups when 
compared to the GC. In conclusion, whereas serum pro-inflammatory cytokine levels are unaltered in 
T2DM patients, differences in inflammatory gene profiles exist among the T2DM patient groups.
Type 2 diabetes (T2DM) is the most prevalent human metabolic disease and its effects are now the leading cause 
of human morbidity and mortality1. T2DM, characterized by hyperglycaemia, is strongly associated with both 
macrovascular (such as coronary artery disease, peripheral arterial disease, and stroke) and microvascular com-
plications (such as diabetic retinopathy, nephropathy and neuropathy)2. Studies have suggested that low-grade 
inflammation, characterized by pro-inflammatory cytokine production, is involved in the pathogenic processes 
causing T2DM3,4. Further, excessive production of these cytokines in T2DM has been associated with the devel-
opment of microvascular and macrovascular complications and may predict the development of diabetes3. It has 
been shown that inflammatory processes in the pancreatic islets, adipose tissue (AT), liver and muscle provoke 
insulin resistance (IR) and β-cell dysfunction and may therefore antedate the diagnosis of diabetes5. The AT is a 
major source of cytokines such as TNF-α, IL-6 and monocyte chemoattractant protein-1 (MCP-1)6–8. Further, 
blood monocytes and neutrophils are sentinel cells that drive inflammation and concomitant pro-inflammatory 
cytokine production in vivo3,9. Many studies have also shown that the gene expression and phenotypic profiles of 
monocytes and neutrophils are altered in response to glucose and in a T2DM milieu9–13. Given this, we opted to 
study whether alterations in inflammatory gene expression occurred in both monocytes and neutrophils in the 
context of T2DM.
Toll-like receptors (TLRs) are a variety of pathogen pattern recognition receptors that serve to detect patho-
gen associated molecular patterns (PAMPs) present on pathogens including bacteria and viruses and to detect 
danger-associated molecular patterns (DAMPs)14,15. Studies have also shown that TLR2 and TLR4 expression 
levels are elevated in patients with T2DM16,17. In fact, TLR4 has been shown to play an important role in the 
pathogenesis of atherosclerosis, diet-induced obesity, and the related insulin resistance18. In the present study, we 
opted to explore the expression levels of key cytokines, chemokines and all TLRs in T2DM subjects and to explore 
whether alterations are linked with micro- and macrovascular complications, and duration of diabetes.
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Results
Participant characteristics. The role of various risk factors for the development and progression of dia-
betes have been demonstrated by several epidemiologic studies19,20. These factors include type and duration of 
diabetes, age, gender, glycaemic control, hypertension, body mass index, smoking, serum lipids and presence 
of microalbuminuria; all these risk factors were examined in the current study (Table 1). Females were 67.6% 
in NGT and 42.9% in T2DM group. The median age was higher in T2DM subjects compared to NGT controls 
(p < 0.001) (Table 1). The duration of diabetes was calculated for all groups and as it reflects the course of disease, 
the groups with complications and poor glycaemic control group had longer duration of diabetes compared to 
good glycaemic control group (p < 0.001). The profile for smoking was similar in both NGT and T2DM groups: 
20.5% were smokers in NGT compared to 20.5% in T2DM groups, and 30.7% were ex-smoker in NGT as com-
pared to 43.5% in T2DM. There were significant differences in the BMI and WHR among the groups (p < 0.01) 
wherein the T2DM subjects had higher BMI and WHR compared to NGT controls. The median systolic BP 
(but not diastolic) was significantly raised in GC, GCC and PCC (p < 0.05). The fasting glucose was higher in all 
T2DM subjects compared to NGT controls (p < 0.05). All T2DM subjects had raised total cholesterol and triglyc-
erides, and low HDL compared to NGT controls (p < 0.05). LDL levels were lower in T2DM subjects compared 
to NGT; this may be attributed to lipid lowering agents.
Previous epidemiological studies have demonstrated increased concentrations of CRP in patients with 
T2DM21. In the present study, we aimed to evaluate patients with ‘steady state’ T2DM. Therefore, individuals 
with acute and chronic illness and a concomitant significant elevation in CRP levels (raised CRP levels multiples 
higher than baseline associated with conditions such as common cold, skin infections, urinary tract infections, 
joint inflammation, active autoimmune conditions such as Crohn’s disease, conditions with arterial inflammation 
such as polymyalgia rheumatism and malignancy) were excluded from the study. The aforementioned exclusion 
criteria was adopted since very high CRP (indicative of illness in both controls and diabetic patients) may act as a 
confounder in evaluating the baseline ‘steady state’ of pro- and anti- inflammatory forces. Notably, the inclusion 
and exclusion criteria that were adopted in the study were thorough and strictly adhered to; patients that met with 
our inclusion and exclusion criteria with mildly raised CRP were not excluded in this study. In the present study, 
a significant difference in CRP levels was not observed between different groups (Table 1).
A detailed drug history was obtained for all patients and it was observed that a higher percentage of patients 
in PC (52.4%) and PCC (71.9%) were administered insulin compared to GC (7.4%) and GCC (28.1%) groups 
(Table 2). In all groups, most T2DM subjects were administered lipid lowering agents: GC (85.2%), GCC (93.8%), 
PC (61.9%) and PCC (87.5%) and also administered angiotensin converting enzyme (ACE) inhibitor and angi-
otensin receptor blocker (ARB) in view of HTN or micro/macro albuminuria: GC (74.1%), GCC (87.5%), PC 
(76.2%), and PCC (81.3%) (Table 2).
All PCC patients had one or more microvascular complications (retinopathy, neuropathy and nephropathy). 
Additionally, 53.1% (17 patients) of these had one or more macrovascular complications. In GCC group, 56.3% 
(18 patients) had one or more microvascular complications, 34.4% (11 patients) had both macro & microvascular 
complications and 9.4% (3 patients) had only macrovascular complications. Among microvascular complications, 
retinopathy was higher in PCC patients (40.6%) compared to GCC patients (18.6%). No significant difference was 
Characteristics NGT GC GCC PC PCC p value
Number 34 27 32 21 32
Sex (M/F) 11/23 12/15 20/12 13/8 19/13 0.068
Age (years) 53 [47–59] 62 [51–71] 65 [57–73] 56 [50–60] 60 [55–68] <0.001
Duration of DM 
(months) ‒ 24 [12–72] 96 [30–168] 108 [60–132] 132[84–180] <0.001
Smoker Y/N 7/24 3/21 6/26 5/16 9/22 0.659
Ex smoker Y/N 8/26 8/19 14/18 4/17 8/24 0.271
BMI (kg/m2) 26 [24–30] 32 [29–38] 31 [28–35] 35 [31–37] 34 [29–37] <0.001
Waist (cm) 91 [82–100] 106 [99–115] 108 [99–115] 110 [99–120] 113 [102–122] <0.001
WHR 0.92 [0.84–0.96] 0.96 [0.90–1.04] 1.03 [0.95–1.06] 1.04 [0.93–1.18] 1.02 [0.97–1.08] <0.001
SBP (mmHg) 129 [120–137] 145 [131–156] 142 [131–154] 130 [120–145] 147 [124–158] 0.005
DBP (mmHg) 80 [77–85] 80 [71–85] 78 [73–84] 78 [73–88] 77 [68–86] 0.808
Fasting glucose (mM) 4.8 [4.7–5.1] 6.5 [5.8–7.2] 7.6 [6.1–8.2] 10.9[8.3–12.9] 10.6 [7.9–14.6]
HbA1c (%) 5.6 [5.4–5.7] 6.4 [6.0–6.9] 6.9 [6.4–7.4] 10.2 [9.2–11] 9.6 [8.9–10.8]
CRP 0.10 [0.06–0.25] 0.20 [0.09–0.30] 0.18 [0.06–0.50] 0.15 [0.06–0.60] 0.20 [0.10–0.40]
Total cholesterol (mM) 5.9 [5.1–6.6] 3.9 [3.5–4.7] 3.7 [3.1–4.3] 4.2 [3.7–4.8] 3.9 [3.5–4.7]
LDL cholesterol (mM) 3.6 [2.8–4.3] 2.2 [1.9–2.9] 1.8 [1.5–2.4] 2.3 [1.8–2.9] 2.0 [1.5–2.7]
HDL cholesterol (mM) 1.6 [1.3–1.9] 1.3 [1.0–1.5] 1.1 [0.9–1.3] 1.1 [1.0–1.3] 1.1 [0.9–1.2]
Triglycerides (mM) 0.9 [0.7–1.2] 1.5 [1.1–2.0] 1.4 [0.8–2.0] 1.5 [0.8–1.9] 1.8 [1.2–2.5]
Table 1. Characteristics of Study Participants. Data are expressed as median [Inter quartile range]. BMI, Body 
Mass Index, SBP, Systolic Blood Pressure, DBP, Diastolic Blood Pressure, WHR, Waist-to-hip ratio Data are 
expressed as median [Inter quartile range]. p value corresponds to the differences between groups. HbA1c, 
glycosylated haemoglobin, HDL, high-density lipoprotein, LDL, low-density lipoprotein, CRP, C-reactive 
protein.
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observed in neuropathy in between two subgroups. 15.6% of PCC patients had diabetic foot disease compared 
to 6.3% GCC patients. Of the PCC patients, 68.8% had nephropathy compared to 56.3% in GCC subgroup. The 
proportion of patients having CKD was higher in PCC subgroup than GCC subgroup (CKD stage 3; 45.5% vs. 
27.7%, CKD stage 4; 9% vs. 0%) (Table 3).
Levels of cytokines in sera from NGT and T2DM patients. Following the analysis of cytokines/
chemokine levels in serum, there was no statistical significant difference in serum TNFα, IL-6, and IL-1β levels 
among the different groups (Fig. 1A–C). The median values of serum TNFα and IL-6 were comparable in GC, 
GCC and PCC patients compared to NGT. While comparable levels of serum IL-1β were observed in GC and 
GCC, levels were decreased in PC and PCC, when compared with NGT. Serum IFN-β was significantly increased 
in PC and comparable in GC group, when compared to NGT control (Fig. 1D) and decreased in the GCC and 
PCC group (p < 0.05). However, following adjustment for covariates, serum IFN-β levels became statistically 
insignificant. Following the analysis of serum IL-10, RANTES, IL-8, IL-12 p70 and IFNγ, there was no statistical 
significant difference in serum levels among the different groups (Fig. 1E–I). Whereas a trend towards increased 
serum IL-10 was observed in GC and PC patients, a marginal trend towards suppressed IL-10 was observed 
in GCC and PCC patients, compared with NGT (Fig. 1E). Following assessment of RANTES, whereas a trend 
towards increased levels in PC and PCC patients was observed when compared with NGT control group, levels 
were comparable in GC, GCC and NGT (Fig. 1F). Whereas a trend towards decreased IL-8 was observed in GCC, 
PC and PCC, when compared with NGT, levels were comparable in GC and NGT (Fig. 1G). A trend towards 
decreased levels of both IL-12 and IFNγ was detected in the serum taken from T2DM subjects when compared 
to the NGT control group.
Next, multifactorial ANOVA analysis of the serum cytokines measured in the present study was undertaken 
after adjustment for age, sex, WHR, BMI, duration of diabetes, creatinine and medications (insulin, sulfonylurea, 
metformin, GLP-1 analogues, DPP IV inhibitors, aspirin and statins). No significant difference in cytokine levels 
among the study groups was shown and there was no correlation between serum cytokine levels and BMI in 
T2DM subjects.
Characteristics NGT GC GCC PC PCC
n 34 27 32 21 32
Lipid lowering Agents — 23 30 13 28
Aspirin — 20 25 13 29
Metformin — 22 26 18 19
Sulphonylurea — 7 14 16 19
PPAR γ agonists — 0 3 1 1
GLP 1 analogs — 2 1 2 1
DPP IV inhibitors — 0 3 2 2
Insulin — 2 9 11 23
ACE inhibitors — 16 20 8 19
ARB — 4 8 8 7
HTN — 17 6 7 20
Table 2. Baseline characteristics: medications and HTN in different subgroups. PPAR γ agonists, Peroxisome 
proliferator-activated receptor gamma agonists, GLP-1 analogs, Glucagon-like peptide-1 analogs, DPP IV 
inhibitors, Inhibitors of dipeptidyl peptidase 4, ACE inhibitor, Angiotensin-converting-enzyme inhibitor, ARB, 







Stage 1 — —
Stage 2 8 7
Stage 3 5 10
Stage 4 — 2
Stage 5 — —
Table 3. CKD staging and diabetic nephropathy of GCC and PCC study participants. CKD, Chronic Kidney 
Disease, MicroAlb, Microalbuminuria, MacroAlb, Microalbuminuria.
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Gene expression of TNFα, IL-6, IL-1β, IFN-β and Rantes in monocytes and neutrophils from 
NGT and T2DM patients. The transcriptional regulation of cytokines involved in regulating the inflamma-
tory response were analysed using a quantitative PCR approach wherein the 2−(ΔΔCt) method was used to ana-
lyse the relative changes in gene expression22. As expected, monocytes expressed mRNA encoding TNFα, IL-6, 
IL-1β, IFN-β and RANTES. A significant increase in TNFα mRNA expression was observed in the monocytes 
obtained from PC and PCC subjects when compared to NGT (Fig. 2A). A significant increase in IL-6 mRNA 
expression was observed in the monocytes obtained from GC and PC subjects when compared to NGT (Fig. 2B). 
A significant decrease in IL-1β mRNA expression was observed in the monocytes obtained from all T2D subjects 
when compared to NGT (Fig. 2C). Interestingly, IFN-β mRNA expression was increased in monocytes from GC, 
PC and PCC subjects when compared to NGT (Fig. 2D). Similarly, the highest levels of RANTES mRNA was 
observed in monocytes obtained from PC and PCC subjects (Fig. 2E). Levels of IL-6 (p < 0.05), IL-1β (p < 0.05), 
IFN-β (p < 0.001) and RANTES (p < 0.001) mRNA expression in monocytes remained significant among dif-
ferent groups following multifactorial ANOVA after adjustment for age, sex, WHR, BMI, duration of diabetes, 
creatinine and medications (insulin, sulfonylurea, metformin, GLP-1 analogues, DPP IV inhibitors, aspirin and 
statins). Additionally, a statistically significant correlation was found between IL-1β mRNA in monocytes and 
BMI in T2DM subjects (Spearman’s r = 0.41, p < 0.05). In summary, the highest level of IL-6 mRNA was observed 
Figure 1. Levels of cytokines in sera from NGT and T2DM patients. TNF-α (A), IL-6 (B), IL-1β (C), IFN-β 
(D), IL-10 (E), Rantes (F), IL-8 (G) IL-12 (H) and IFNγ (I) levels in NGT (n = 34), GC (n = 27), GCC (n = 32), 
PC (n = 21) and PCC (n = 32) patient groups. *p < 0.05, **p < 0.01, ***p < 0.001 vs. NGT.
Figure 2. Gene expression of TNFα, IL-6, IL-1β, IFN-β and Rantes in monocytes and neutrophils from NGT 
and T2DM patients. Analysis of TNFα (A,F), IL-6 (B,G), IL-1β (C,H), IFN-β (D,I) and RANTES (E,J) gene 
expression in monocytes (A–E) and neutrophils (F–J) from NGT and T2DM patients (n = 8 per group). Top 
and bottom horizontal lines of the boxplots indicate 25th and 75th percentiles respectively; lines within the box 
indicate median values. *p < 0.05, **p < 0.01, ***p < 0.001 vs NGT.
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in GC group, whereas highest level of IFNβ mRNA and Rantes mRNA were observed in the PC group, when com-
pared to NGT. In contrast, IL-1β mRNA remained suppressed in the T2DM groups, compared to NGT.
In neutrophils, a significant increase in TNFα mRNA expression was observed in GC subjects when compared 
to NGT (Fig. 2F). A significant increase in IL-6 mRNA expression was observed in neutrophils obtained from 
GC and PC subjects when compared to NGT (Fig. 2G). A significant decrease in IL-1β mRNA expression was 
observed in the neutrophils obtained from PC subjects when compared to NGT (Fig. 2H). IFN-β and RANTES 
mRNA was increased in neutrophils from GC and PC subjects when compared to NGT (Fig. 2I,J). TNFα 
(p < 0.001), IL-6 (p < 0.001), IFN-β (p < 0.001) and RANTES (p < 0.001) mRNA expression levels remained 
significant among different groups following multifactorial ANOVA after adjustment for age, sex, WHR, BMI, 
duration of diabetes, creatinine and medications (insulin, sulfonylurea, metformin, GLP-1 analogues, DPP 
IV inhibitors, aspirin and statins). A correlation between cytokine mRNA levels and BMI was not evident in 
neutrophils. Collectively, our data suggests that whereas comparable TNFα, IL-6, IFN-β and RANTES mRNA 
expression levels were evident among the GCC, PCC and NGT groups, TNFα, IL-6, IFN-β and RANTES mRNA 
expression levels were highest in neutrophils obtained from GC subjects, when compared to NGT controls. In 
contrast, IL-1β mRNA expression levels were not elevated among the T2DM subject groups.
Gene expression of TLR1-10 in monocytes and neutrophils from NGT and T2DM patients. In 
monocytes, TLR1, 3, 5 and 7–10 mRNA levels were elevated in GC subjects when compared to NGT; levels of 
TLR1, 3, 5, 7, 9, and 10 remained statistically significant following adjustment for age, sex, WHR, BMI, duration 
of diabetes, creatinine and medications (insulin, sulfonylurea, metformin, GLP-1 analogues, DPP IV inhibitors, 
aspirin and statins) using multifactorial ANOVA (Fig. 3A–J). In contrast, TLR1, 5, 7 & 10 levels were elevated in 
monocytes obtained from GCC subjects compared to NGT (p < 0.05) (Fig. 3A–J). In monocytes obtained from 
PC subjects, whereas TLR7 expression was enhanced, expression of all other TLRs was normal when compared to 
NGT. Interestingly, in PCC monocytes, expression of all TLRs examined was comparable to NGT.
In neutrophils, TLRs1, 3–10 mRNA levels were elevated in GC subjects when compared to NGT; levels 
remained statistically significant following adjustment for covariates as mentioned previously (Fig. 3K–T). 
Whereas TLR2, 4–5 levels were elevated in GCC when compared to NGT, only TLR4 mRNA expression was ele-
vated in the PCC subjects (Fig. 3K–T). TLR5, 7 and 9, but not other TLRs, were elevated in neutrophils obtained 
from PC subjects. A correlation between TLRs mRNA levels in either neutrophils or monocytes, and BMI was 
not evident in the T2DM subjects.
Correlation between fasting glucose levels, insulin and inflammation. In the GC group, there was 
a significant correlation between fasting glucose and monocyte IL-1β (r = 0.738; p = 0.04) and TLR8 (r = 0.94, 
p = 0.001), and neutrophil RANTES (r = −0.742, p = 0.04) mRNAs. In the GCC group, there was a signifi-
cant correlation between fasting glucose and monocyte RANTES (r = 0.747; p = 0.03) and neutrophil TLR5 
(r = −0.730, p = 0.04) mRNAs. In the PCC group, there was a significant correlation between fasting glucose and 
serum RANTES (r = 0.403; p = 0.02) and monocyte IL-1β mRNA (r = 0.857, p = 0.02).
In the GC group, there was a significant correlation between duration of diabetes and monocyte RANTES 
(r = −0.715, p = 0.05) and TLR8 (r = 0.741, p = 0.04) mRNA, and neutrophil TLR2 mRNA (r = −0.838, p = 0.01). 
In the GCC, there was no correlation. In the PC group, there was a correlation between neutrophil TLR8 
(r = 0.771, p = 0.03) and TLR9 (r = 0.747, p = 0.04) mRNAs. In the PCC group, there was a correlation between 
duration of diabetes and neutrophil TLR1 (r = −0.730, p = 0.04), TLR3 (r = 0.766, p = 0.03) and TLR5 (r = 0.843, 
p = 0.01) mRNAs.
Discussion
The main objective of this study was to investigate the role of inflammatory biomarkers in the pathophysiology of 
T2DM. To the best of our knowledge, this is the first study that has sought to evaluate serum cytokine levels and 
cytokines/TLRs gene expression in both monocytes and neutrophils among T2DM cohorts.
In this study, we showed that in neutrophils, the highest levels of the proinflammatory cytokines, TNFα, IL-6 
and IFN-β mRNA were present in the GC subjects when compared to NGT control. Similarly, in monocytes, IL-6 
and IFN-β mRNA levels were elevated in GC subjects, when compared to NGT. Our results correlate with previ-
ous studies which showed that TNFα mRNA and IL-6 levels were elevated in T2DM subjects23,24. Chemokines, 
such as IL-8 and RANTES play a critical role in driving and inflammatory milieu since they mediate the arrival 
of inflammatory cells to the site of both acute and chronic inflammation25. Herein, our study demonstrated that 
RANTES mRNA expression was elevated in neutrophils (but not monocytes) obtained from the GC subjects. Our 
study correlates, in part, with previous studies, which demonstrate that serum RANTES levels are increased in 
T2DM subjects25,26. Intriguingly, our study showed that while RANTES mRNA levels were increased in some of 
the T2DM subjects, levels of RANTES in serum were comparable among the different groups.
Our study also demonstrated that TNFα, IL-6, IFN-β and RANTES mRNA and serum levels were not sig-
nificantly elevated in GCC subjects when compared to NGT. In the PC subjects, while levels of IL-6, IFN-β and 
RANTES mRNA were raised in both monocytes and neutrophils, serum protein levels were not significantly 
different among the groups.
In the PCC subjects, while levels of IFN-β and Rantes mRNA were raised in monocytes, levels remained 
unchanged in neutrophils, when compared to NGT. Despite an increase in cytokine mRNA level, serum protein 
levels were not significantly different among the groups. Further TNF-α mRNA was significantly overexpressed 
in PC and PCC monocytes, but after adjustment for covariates, it became statistically insignificant.
Regarding IL-12, we observed low serum levels of IL-12 and IFN-γ in T2DM subjects, which was statistically 
insignificant. Our findings are in contrast to that previously reported by Tsiavou et al., who demonstrated low 
www.nature.com/scientificreports/
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serum levels of IFN- γ and IL-12 in T2DM subjects27. In contrast, Wegner et al., demonstrated elevated IL-12 
serum levels in T2DM subjects28. Regarding IL-10, an anti-inflammatory cytokine, our study demonstrated that 
IL-10 levels were comparable in T2DM and NGT subjects, however it remained statistically insignificant. This is 
in contrast to Yaghini et al., who previously showed that IL-10 levels were decreased in T2DM subjects29.
Contrasting with TLR2 and TLR4, there is a paucity of data exploring the role of other TLRs in T2DM. 
However, upregulated expression of TLR1–9 and TLR11–13 was shown in two murine models of obesity30. 
Given that TLRs are key enablers of the inflammatory response, serving to drive the production of inflammatory 
cytokines, we sought to explore the expression levels of TLR1-10 in monocytes and neutrophils obtained from 
T2DM and healthy participants. In monocytes, our study demonstrated that, in general, levels of TLR mRNA 
expression were enhanced in the monocytes obtained from GC subjects. Similarly, in neutrophils, expression of 
most TLR mRNAs was increased in GC subjects when compared to NGT. Correlating with our data generated 
from T2DM patients with good glycaemic control (GC), previous studies have demonstrated that the expression 
of TLR2 and TLR4 was increased in monocytes derived from patients with T2DM, mean duration 29 months17. 
Further, other studies demonstrated that TLR2 and TLR4 mRNA levels were elevated in PBMCs taken from 
T2DM patients31, though mean disease duration was not indicated32.
Interestingly, in our study, T2DM patients with mean disease duration >8 years, namely T2DM patients with 
poor glucose control, and subjects with complications showed a trend towards suppressed TLR mRNA expres-
sion when compared to GC subjects. In monocytes, whereas TLR7 levels were elevated in PC, levels of all TLRs 
Figure 3. Gene expression of TLR1-10 in monocytes and neutrophils from NGT and T2DM patients. Analysis 
of TLR1 (A,K), TLR2 (B,L), TLR3 (C,M), TLR4 (D,N), TLR5 (E,O), TLR6 (F,P), TLR7 (G,Q), TLR8 (H,R), 
TLR9 (I,S), TLR10 (J,T) gene expression in monocytes (A–J) and neutrophils (K–T) from NGT and T2DM 
patients (n = 8 per group). Top and bottom horizontal lines of the boxplots indicate 25th and 75th percentiles 
respectively; lines within the box indicate median values. *p < 0.05, **p < 0.01, ***p < 0.001 vs NGT.
www.nature.com/scientificreports/
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were comparable to NGT among PCC subjects. Similarly, in neutrophils, GCC subjects moderately overexpress 
TLR4 & 5, whereas PC overexpressed TLR5, 7 & 9 compared to NGT. PCC subjects overexpressed only TLR4 
in neutrophils, and no significant change in the expression of TLR3, 6, 8, 9 & 10 was noted in PCC compared to 
NGT. Further, after adjustment for age, sex, WHR, BMI, duration of diabetes, creatinine and medications using 
lognormal data with multifactorial ANOVA, TLR1, 3, 5, 6, 7, 9 and 10 mRNA levels remained statistically signif-
icant among the groups.
Taken together, these data suggest that TLR gene expression is elevated in T2DM patients with good glucose 
control when compared to the general population. However, in T2DM patients with good glucose control with 
complications, levels of TLRs are decreased when compared to individuals with similar glucose control without 
complications. Further, in T2DM patients with poor glucose control in the absence and presence of complica-
tions, levels of TLR gene expression are decreased when compared to T2DM patients with good glucose control. 
In fact, levels of TLR expression among patients with poor glucose control are more comparable to that observed 
in the general population. Given the apparent differences in the expression of TLRs among the T2DM groups, 
namely the enhanced TLR expression in patients with good glucose control versus the downregulation of TLRs 
in patients with poor glucose control and in patients with complications, it is plausible to speculate that decreased 
TLR expression in the latter groups may have occurred to curtail sustained TLR activation and concomitant 
inflammatory processes. Whether decreased TLR expression leads to compromised innate immune signalling 
mechanisms and concomitant predisposition to infections requires further investigation.
Our study has shown that IL-6 and IFN-β mRNA levels are elevated in monocytes and neutrophils from 
GC and PC and that TNFα mRNA levels are elevated in neutrophils from GC group, compared with NGT. 
Intriguingly, our study failed to show elevated serum TNFα, IL-6, IFNβ, IL-8, IL-10, IL-12 and IFNγ levels in 
T2DM subjects despite perturbations in cytokine/TLR mRNAs levels being evident in the monocytes and neu-
trophils taken from T2DM patients. In terms of TLR expression, studies have shown that metformin33, statins, 
PPAR-γ agonists34 and angiotensin receptor blockers35 lower the expression of TLR2 and TLR4 in T2DM patients. 
Further, previous studies have shown that insulin infusion significantly suppressed TLRs 1, 2, 4, 7, and 9 mRNA 
expressions in mononuclear cells obtained from T2DM individuals18. Notably, in the current study, a greater 
number of T2DM patients from the GCC, PC and PCC were prescribed insulin compared to the GC patient 
group. Given that our T2DM subjects were prescribed and were administering these medications, it is plausible 
to speculate that long term administration of these drugs, for example in the GCC, PC and PCC groups, may 
contribute to the impaired TLR expression among the cohort when compared to the GC group.
In conclusion, our study shows that while perturbations in the gene expression of cytokines are evident in 
patients with T2DM, serum levels of the cytokines examined remain comparable between individuals with and 
without T2DM. Further, our study also suggests that levels of TLRs, receptors intimately linked with the inflam-
matory process, are perturbed in patients with good glucose control in the absence of complications. However, 
levels of TLR mRNA expression decrease as the disease duration progresses over time. Whether this perturbation 
is the result of disease process itself, the prescribed medications, or whether patients with perturbed inflam-
matory markers are more susceptible to developing diabetes and associated microvascular and macrovascular 
complications, remains to be investigated. However, the consistent and significantly suppressed cytokine and TLR 
gene expression in patients with poor glycaemic control and with complications suggests a “burnt out” disease 
state. Landmark clinical trials (UKPDS, Steno 2, ADVANCE) have already shown that intensive glycaemic control 
leads to a reduction in morbidity and mortality over time36–40. This study raises the potential role of early aggres-
sive glucose lowering and cardiovascular risk factor management in reversing the peak inflammation associated 
with the early stages of T2DM and thus reducing the risk of cardiovascular and microvascular complications later 
in life. Further investigation is required to examine this hypothesis.
Research Design and Methods
Study subjects and design. Healthy control participants were screened for diabetes using the standard 
oral glucose tolerance test (American Diabetes Association (ADA)). Healthy control participants with abnor-
mal blood results (diabetes or pre-diabetes) and individuals with a history of chronic illness and/or individuals 
taking medication were excluded from the NGT group. T2DM participants had established diagnosis according 
to the ADA criteria. All participants were >18 years old and were not pregnant. Exclusion criteria included the 
following: Evidence of current infection (white cell count >11 or CRP >normal range), current treatment with 
antibiotics, neutropenia (a leucocyte count of less than 2000 per cubic millimetre), pregnancy or breast-feeding, 
non diabetic renal disease or liver disease (aspartate aminotransferase or alanine aminotransferase of more than 
three times the upper limit of the normal range), ongoing or previous cancer and the use of oral/inhaled gluco-
corticoids, immunosuppressive treatment or immunodeficiency.
Based on these criteria, 146 participants were recruited from a regional hospital. Healthy volunteers without 
diabetes acted as the control group (normal glucose tolerance, NGT; n = 34) and 112 T2DM patients (mean dura-
tion 95 months) with four different profiles were recruited: T2DM with good glycemic control (HbA1c <7.5%) 
and no macrovascular complications (heart disease, transient ischaemic stroke (TIA)/stroke or peripheral arte-
rial disease (PAD)) and microvascular complications (retinopathy, neuropathy or nephropathy) GC, n = 27), 
T2DM with good glycemic control and complications (GCC, n = 32), T2DM with poor glycemic control (HbA1c 
>7.5%) without complications (PC, n = 21), and T2DM with poor glycaemic control and complications (PCC, 
n = 32). In case of the healthy volunteers, each participant met the inclusion and exclusion criteria for the study. 
Each healthy control participant was screened for diabetes and prediabetes using the standard oral glucose tol-
erance test41. Participants with abnormal results were excluded from the study. Personal and medical data was 
obtained by patient interview, by using hospital medical notes, and from using hospital laboratory test results. 
The demographic information was obtained from research participants and their weight, height, blood pressure 
& waist and hip circumferences were determined. BMI was calculated as body weight (in kilograms) divided by 
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body height (in meters) squared. Waist-to-hip ratio (WHR) was calculated as waist divided by hip circumfer-
ence. Informed consent was obtained from all participants. The protocol was approved by the Midlands Research 
Ethics Committee, Health Service Executive, Ireland, and by the Ethical Review Board, Maynooth University, 
Maynooth, Ireland and all experiments were performed in accordance with relevant guidelines and regulations.
Biochemical Analysis. Routinely, fasting blood samples were collected from consenting T2DM patients 
and healthy control subjects in the morning between 8–10 am to minimise the impact of diurnal variation on 
the study. More specifically, about 40 ml peripheral blood was collected from each participant including healthy 
volunteers and was used to measure various biochemical parameters and cytokines. A haemoglobin analyser 
HA-8160 (Menarini Pharmaceuticals, Ireland) was used to measure HbA1C (HPLC Chromatography Method) 
and Advia analysers were used to measure the whole blood counts. Lipid profile, urea, creatinine, sodium, potas-
sium, asparate aminotransferase, alanine aminotransferase, bilirubin, alkaline phosphatase, gamma glutamyl 
transferase, CRP, ferritin, coagulation screen, thyroid profile and plasma glucose were measured using a Roche 
Modular 1800 analyser. An early morning urine sample for ACR measurement was also collected at the same 
time.
Cytokine measurements. For cytokine analysis, the blood was placed on ice and then centrifuged 
(3000 rpm, at 4 °C) within 1 hour of venesection. Serum was collected and stored at −80 °C. Serum was used for 
measuring TNFα, IL-6, IL-1β, IL-10, IL-8, IL-12p70 and IFN-γ using a 96-Well MULTI-ARRAY 7-Multiplex 
Assay (Meso Scale Discovery). Serum was used for measuring IFN-β and Rantes using single-plex 96-well plates 
(Meso Scale Discovery).
Mononuclear cell isolation and TLR mRNA quantification. Peripheral Blood Mononuclear Cells 
(PBMC) were isolated from heparinized peripheral blood by density gradient centrifugation. Human CD14 pos-
itive monocytes were isolated from PBMCs using the EasySep™ Human CD14 Positive Selection Cocktail, and 
neutrophils were isolated using the EasySep™ Human Neutrophil Enrichment Kit by negative selection. Initially, 
to ensure the robustness of the isolation procedure, a number of samples were analysed by flow cytometry to 
establish and confirm the purity of the monocyte and neutrophil population post selection. Next, total RNA was 
extracted from monocytes and neutrophils using the RNeasy isolation kit (Qiagen). RNA (1 μg per 25 μl reaction) 
was converted to first strand cDNA and stored at −20 °C42. Real-time PCR quantification was performed with 
DyNAmoHS SYBR Green kit (Finnzymes) using the OPTICON® system (MJ Research). For the amplification of 
TLRs & cytokines, in house-designed primers were used (Supplemental Table S1) using the housekeeping gene 
hypoxanthine phosphoribosyl transferase (HPRT) as a reference point42.
Statistical analysis. Data are expressed as median (interquartile range) and represented as box-and-whiskers 
plots. The dark midline in the box represents the distribution’s median value. The top and bottom edges of the box 
respectively represent the 75th and 25th percentile values. The top and bottom of the vertical lines, the whisker 
respectively represent the upper and lower maximum value. χ2 test or Fisher exact test (as appropriate) were used 
to compare proportions. The Mann–Whitney test was used in case of non-normally distributed parameters to 
compare median between two groups. Kruskal-Wallis test was used for multiple inter-group comparisons in case 
of parameters that did not show normal distribution. If a significant difference was found in inter-group com-
parisons, post hoc multiple comparison analysis with the Dunns multiple comparison test was performed. Data 
were transformed to log normal format and multifactorial ANOVA was applied to evaluate the effect of variables 
(age, sex, BMI, WHR and duration of diabetes) on different inflammatory markers. Correlations between values 
were examined by calculating Spearman correlation coefficients. All the statistical analysis was performed using 
the Prism 6.0 computer program (GraphPad, La Jolla, CA) and p value less than 0.05 was considered significant.
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